Articles related to EMERGING THERAPIES

The FDA granted Fast Track designation to elunetirom, an oral CNS thyroid hormone receptor agonist, for adjunctive treatment of bipolar depression, while the agent remains in a 30-participant open-label phase 2 trial with no human efficacy data yet available.

Researchers at the National University of Singapore developed a spinach-derived nanotechnology delivering plant photosynthetic machinery into corneal cells via eye drops, demonstrating reversal of corneal damage to near-healthy levels within five days in preclinical models of dry eye disease.

The 2026 KDIGO anemia in CKD guideline replaces two long-standing iron deficiency classifications, endorses proactive high-dose IV iron in maintenance hemodialysis, and provides first-ever positioning guidance on HIF-PHIs, 14 years after the previous version.

Brain glucose levels regulated oligodendrocyte progenitor cell proliferation and maturation in mouse and cell models, with ketone bodies restoring myelin production when glucose use was disabled.

Two retina specialists debated whether LIGHTSITE III evidence supports photobiomodulation as treatment for intermediate dry AMD, weighing modest BCVA gains against natural visual acuity variability, study quality concerns, and FDA authorization status.

Bayer agreed to acquire Perfuse Therapeutics in a deal valued at up to $2.45 billion, gaining full rights to a phase 2 endothelin receptor antagonist for glaucoma and diabetic retinopathy.